Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium’s Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming educational session highlighting the role of radiopharmaceuticals, including Actimab-A, in the treatment of acute myeloid leukemia (AML) and in other cancers. The conference will be held Friday, May 30 – Wednesday June 3, 2014 at McCormick Place, Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
